Myriad Genetics Dirección

Dirección controles de criterios 2/4

El CEO de Myriad Genetics' es Paul Diaz , nombrado en Aug 2020, tiene una permanencia de 4.08 años. compensación anual total es $12.11M, compuesta por 9% salario y 91% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.47% de las acciones de la empresa, por valor de €11.01M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 4.6 años, respectivamente.

Información clave

Paul Diaz

Chief Executive Officer (CEO)

US$12.1m

Compensación total

Porcentaje del salario del CEO	9.0%
Permanencia del CEO	4.1yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Diaz en comparación con los beneficios de Myriad Genetics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$155m
Mar 31 2024	n/a	n/a	-US$235m
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

Compensación vs. Mercado: La compensación total de Paul($USD12.11M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD2.49M).

Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.

CEO

Paul Diaz (62 yo)

4.1yrs

Permanencia

US$12,108,359

Compensación

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Diaz	CEO, President & Director	4.1yrs	US$12.11m	0.46% $ 9.7m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	sin datos
Dale Muzzey	Chief Scientific Officer	2.7yrs	US$2.23m	0.12% $ 2.5m
Mark Verratti	Chief Commercial Officer	7.1yrs	US$2.88m	0.33% $ 7.0m
Scott Leffler	Chief Financial Officer	less than a year	sin datos	sin datos
Natalie Munk	Principal Accounting Officer	2.3yrs	sin datos	0.048% $ 1.0m
Kevin Haas	Chief Technology Officer	3.6yrs	US$1.64m	0.15% $ 3.1m
Matthew Scalo	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Jennifer Fox	Chief Legal Officer	no data	sin datos	sin datos
Glenn Farrell	Senior VP & Chief Marketing Officer	1.8yrs	sin datos	sin datos
Shereen Solaiman	Chief People Officer	1.5yrs	sin datos	0.0031% $ 67.0k
Patrick Burke	Executive Vice President of Strategy & Innovation	3.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MYD se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Diaz	CEO, President & Director	4.1yrs	US$12.11m	0.46% $ 9.7m
Paul Bisaro	Independent Director	1.9yrs	US$258.48k	0.027% $ 574.5k
Lee Newcomer	Independent Director	5yrs	US$447.99k	0.073% $ 1.6m
Daniel Skovronsky	Independent Director	4.2yrs	US$433.49k	0.077% $ 1.7m
Colleen Reitan	Independent Director	5yrs	US$443.49k	0.030% $ 630.6k
Heinrich Dreismann	Independent Director	14.3yrs	US$443.49k	0.12% $ 2.5m
S. Phanstiel	Independent Chair of the Board	15yrs	US$563.49k	0.16% $ 3.4m
Rashmi Kumar	Independent Director	4yrs	US$433.49k	0.068% $ 1.4m

4.6yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de MYD se considera experimentada (4.5 años de antigüedad promedio).

Myriad Genetics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Recent updates

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Second quarter 2024 earnings released: US$0.41 loss per share (vs US$1.42 loss in 2Q 2023)

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Financial position

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Independent Chair of the Board recently sold €529k worth of stock

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021

Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test